PMID 32819304

Research
All papers

The impact of high-intensity interval training exercise on breast cancer survivors: a pilot study to explore fitness, cardiac regulation and biomarkers of the stress systems

Question

Can supervised HIIT improve fitness and stress-system biomarkers in breast cancer survivors compared with moderate continuous training or wait-list control?

Summary

In a small pilot RCT of sedentary breast cancer survivors, 12 weeks of supervised cycling HIIT improved VO2peak more than moderate cycling or a wait-list control. Attendance was similar between exercise groups and no adverse events were reported, but the sample was very small.

Methodology

  • Seventeen sedentary female breast cancer survivors completed the pilot RCT.
  • 17 participants.
  • Cycle ergometer.
  • Work intervals: 30 seconds as hard as possible.
  • Recovery: 2 minutes active recovery.
  • Intensity: Hard/all-out effort; HR and RPE monitored.
  • 20-30 minutes.
  • 3 sessions/week.
  • 12 weeks.
  • Three-arm randomized controlled pilot trial
  • VO2peak, HRV, Salivary biomarkers, and Safety were tracked.

Outcomes

VO2peak

HIIT increased VO2peak by 19.3%, while CMIT and control did not significantly improve.

F2,12=6.53, p=0.01; HIIT B=3.98, 95% CI 1.88 to 6.02.

Improved

HRV

No significant group changes in HRV were observed.

All p>.05.

No clear change

Stress markers

s-IgA did not change; cortisol slightly increased overall; s-AA response changes were not significant at group level.

s-cortisol time effect p=0.03; s-IgA p>.1; s-AA group changes p>.2.

Mixed

Safety

No adverse events were reported during supervised exercise.

Improved

Insights

  • Short hard cycling intervals can improve VO2peak in selected sedentary breast cancer survivors when supervised.
  • Attendance was comparable between HIIT and moderate-intensity cycling.

Limitations

  • Very small pilot sample.
  • Treatment imbalance across groups.
  • Unobserved saliva collection.
  • Generalizability limited to selected survivors able to cycle.

Safety

  • No adverse events were reported.